Discovery and Validation of 3 Novel DNA Methylation Markers of Prostate Cancer Prognosis

Journal of Urology

Volumn 177, Issue 5, 2007, Pages 1753-1758

  Cottrell, Susan ^a   Jung, Klaus ^b   Kristiansen, Glen ^b   Eltze, Elke ^c   Semjonow, Axel ^c   Ittmann, Michael ^e   Hartmann, Arndt ^d   Stamey, Thomas ^f   Haefliger, Carolina ^a   Weiss, Gunter ^a  

^a EPIGENOMICS AG   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY OF MÜNSTER   (Germany)

^d UNIVERSITY OF REGENSBURG   (Germany)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

DNA methylation; microarray analysis; prostate; prostate specific antigen; prostatic neoplasms

Indexed keywords

GENOMIC DNA; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME 3; CPG ISLAND; DNA METHYLATION; DNA SEQUENCE; EXPRESSED SEQUENCE TAG; GLEASON SCORE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METHYLATION SEQUENCE TAG; MICROARRAY ANALYSIS; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; REAL TIME POLYMERASE CHAIN REACTION; STATISTICAL MODEL;

AGED; BIOPSY; DNA METHYLATION; DNA, NEOPLASM; EXPRESSED SEQUENCE TAGS; FOLLOW-UP STUDIES; GTP-BINDING PROTEINS; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POLYMERASE CHAIN REACTION; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, NEUROPEPTIDE; TUMOR MARKERS, BIOLOGICAL;

EID: 34147170557     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2007.01.010     Document Type: Article

References (19)

1. Pound C.R., Partin A.W., Eisenberger M.A., Chan D.W., Pearson J.D., and Walsh P.C. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281 (1999) 1591
2. Roehl K.A., Han M., Ramos C.G., Antenor J.A., and Catalona W.J. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol 172 (2004) 910
3. Messing E.M., Manola J., Sarosdy M., Wilding G., Crawford E.D., and Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 341 (1999) 1781
4. See W.A., Wirth M.P., McLeod D.G., Iverson P., Klimberg I., Gleason D., et al. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program. J Urol 168 (2002) 429
5. Wirth M.P., See W.A., McLeod D.G., Iverson P., Morris T., Carroll K., et al. Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years. J Urol 172 (2004) 1865
6. Kattan M.W. When and how to use informatics tools in caring for urologic patients. Nat Clin Pract Urol 2 (2005) 183
7. Henrique R., Jeronimo C., Teixeira M.R., Hoque M.O., Carvalho A.L., Pais I., et al. Epigenetic heterogeneity of high-grade prostatic intraepithelial neoplasia: clues for clonal progression in prostate carcinogenesis. Mol Cancer Res 4 (2006) 1
8. Rosenbaum E., Hoque M.O., Cohen Y., Zahurak M., Eisenberger M.A., Epstein J.I., et al. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy. Clin Cancer Res 11 (2005) 8321
9. Liang G., Gonzalgo M.L., Salem C., and Jones P.A. Identification of DNA methylation differences during tumorigenesis by methylation-sensitive arbitrarily primed polymerase chain reaction. Methods 27 (2002) 150
10. Toyota M., and Issa J.P. Methylated CpG island amplification for methylation analysis and cloning differentially methylated sequences. Methods Mol Biol 200 (2002) 101
11. Berlin K., Ballhause M., and Cardon K. Improved bisulfite conversion of DNA (2005), United States Patent and Trademark Office, Alexandria, Virginia patent PCT/WO/EP/05/038051
12. Adorjan P., Distler J., Lipscher E., Model F., Muller J., and Pelet C. Tumour class prediction and discovery by microarray-based DNA methylation analysis. Nucleic Acids Res 30 (2002) e21
13. Model F., Koenig T., Piepenbrock C., and Adorjan P. Statistical process control for large scale microarray experiments. Bioinformatics 18 suppl. (2002) S155
14. Martens J.W., Nimmrich I., Koenig T., Look M.P., Harbeck N., Model F., et al. Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer. Cancer Res 65 (2005) 4101
15. Pepe M.S. The Statistical Evaluation of Medical Tests for Classification and Prediction (2003), Oxford University Press USA, New York
16. Yamashita S., Tsujino Y., Moriguchi K., Tatematsu M., and Ushijima T. Chemical genomic screening for methylation-silenced genes in gastric cancer cell lines using 5-aza-2′-deoxycytidine treatment and oligonucleotide microarray. Cancer Sci 97 (2006) 64
17. Crisponi L., Deiana M., Loi A., Chiappe F., Uda M., Amati P., et al. The putative forkhead transcription factor FOXL2 is mutated in blepharophimosis/ptosis/epicanthus inversus syndrome. Nat Genet 27 (2001) 159
18. Ishii M., Fei H., and Friedman J.M. Targeted disruption of GPR7, the endogenous receptor for neuropeptides B and W, leads to metabolic defects and adult-onset obesity. Proc Natl Acad Sci U S A 100 (2003) 10540
19. Kelly M.A., Beuckmann C.T., Williams S.C., Sinton C.M., Motoike T., Richardson J.A., et al. Neuropeptide B-deficient mice demonstrate hyperalgesia in response to inflammatory pain. Proc Natl Acad Sci U S A 102 (2005) 9942